At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Market Closed 07-24 16:00:00 EDT
19.26
+0.28
+1.48%
盘后19.60
+0.34+1.77%
19:48 EDT
High19.63Low18.36Vol639.11K
Open18.99D1 Closing18.98Amplitude6.68%
Mkt Cap1.04BTradable Cap910.66MTotal Shares54.19M
T/O12.25MT/O Rate1.35%Tradable Shares47.28M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

RA Capital Healthcare Fund Disposes of 213 Vor Biopharma Shares Worth $4,206.75
Reuters  ·  07-22
RA Capital Healthcare Fund Disposes of 213 Vor Biopharma Shares Worth $4,206.75
Vor Biopharma Director David Zaccardelli Files Initial Beneficial Ownership Statement
Reuters  ·  07-10
Vor Biopharma Director David Zaccardelli Files Initial Beneficial Ownership Statement
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
TIPRANKS  ·  07-08
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
Press Release: Vor Bio Appoints David Zaccardelli to Board of Directors
Dow Jones  ·  07-08
Press Release: Vor Bio Appoints David Zaccardelli to Board of Directors
Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next
Simply Wall St.  ·  07-06
Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next
Vor Bio Grants Inducement Awards to New Hires, Including Options for 71,200 Shares at $18.39
Reuters  ·  07-03
Vor Bio Grants Inducement Awards to New Hires, Including Options for 71,200 Shares at $18.39
Vor Bio Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  07-03
Vor Bio Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Vor Biopharma shareholders back directors and governance measures
TIPRANKS  ·  06-13
Vor Biopharma shareholders back directors and governance measures
Vor Biopharma shareholders approved amended 2021 equity incentive plan at annual meeting
Reuters  ·  06-13
Vor Biopharma shareholders approved amended 2021 equity incentive plan at annual meeting
Vor Bio gains boost from telitacicept IgA nephropathy approval
TIPRANKS  ·  06-09
Vor Bio gains boost from telitacicept IgA nephropathy approval
Vor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease
MT Newswires Live  ·  06-08
Vor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease
Vor Bio says China NMPA approves telitacicept for Sjögren’s disease
Reuters  ·  06-08
Vor Bio says China NMPA approves telitacicept for Sjögren’s disease
Vor Bio says telitacicept wins China conditional approval for IgA nephropathy
Reuters  ·  06-08
Vor Bio says telitacicept wins China conditional approval for IgA nephropathy
Telitacicept Receives Nmpa Conditional Approval for the Treatment of Iga Nephropathy in China
THOMSON REUTERS  ·  06-08
Telitacicept Receives Nmpa Conditional Approval for the Treatment of Iga Nephropathy in China
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
TIPRANKS  ·  06-05
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
Vor Bio grants 61,050 stock options, 12,900 RSUs to new hires under inducement plan
Reuters  ·  06-02
Vor Bio grants 61,050 stock options, 12,900 RSUs to new hires under inducement plan
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-02
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
Dow Jones  ·  05-19
Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
Vor Bio price target raised to $18 from $15 at Wedbush
TIPRANKS  ·  05-15
Vor Bio price target raised to $18 from $15 at Wedbush
Vor Biopharma Is Maintained at Neutral by Wedbush
Dow Jones  ·  05-14
Vor Biopharma Is Maintained at Neutral by Wedbush

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--